一项针对149名受试者的3b期临床试验评估了礼来（NYSE：LLY）Taltz（依昔珠单抗）对中度至重度生殖器牛皮癣患者的治疗效果。具体而言，与安慰剂相比，治疗组的患者在治疗12周后对性活动的影响有所降低。结果在圣地亚哥的AAD上发表。治疗组中92.0％的患者报告没有或很少有皮肤症状引起的性困难，而安慰剂组为56.8％（p<0.001). 78.4% of patients receiving Taltz reported that the frequency of sexual activity was either never or rarely limited by genital psoriasis versus 21.4% for placebo (p<0.001).Up to 63% of psoriasis sufferers experience symptoms in the genital area.Taltz is currently approved in the U.S. for the treatment of plaque psoriasis and psoriatic arthritis.Now read: Eli Lilly: Solid 2017, Soft Sales GuidanceOriginal articleiv>